Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pharmacokinetic And Cytotoxic Studies Of Pegylated Liposomal Daunorubicin

H. Song, J. Zhang, Zhikai Han, X. Zhang, Z. Li, Lisheng Zhang, Ming Fu, C. Lin, J. Ma
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Pegylated liposomes have been studied for nearly two decades. However, fewer pharmacological studies about its application in daunorubicin (DNR) than those in doxorubicin have been reported. In order to conduct a complete pharmacokinetic study, radiolabeled DNR was encapsulated in pegylated liposomes. Its in vitro drug release kinetics was determined to be in a slow manner, which was reflected in its cytotoxic effect on four cell lines. The lethal dose, plasma pharmacokinetics as well as tissue distribution of the formulation were evaluated in comparison with free DNR. The results revealed that liposomal daunorubicin significantly reduced the toxicity of the drug, with a half lethal dose of 29.35 mg/kg, compared with 5.45 mg/kg for free drug. Pharmacokinetic study of liposomal DNR demonstrated a slower clearance rate, an elevated area under the concentration–time curve, as well as increased half-lives compared to free drug. In addition, an altered tissue distribution of liposomal DNR was observed, with lower cardiac accumulation. Taken together, pegylated liposome-loaded DNR may be a promising anticancer drug and worth further therapeutic study.
This paper references
10.1097/00001813-199911000-00007
Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.
S. Bandak (1999)
10.1007/s002800050855
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
M. S. Newman (1999)
10.1073/PNAS.88.24.11460
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
J. Huwyler (1997)
10.3109/08982109409037057
Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes.
E. Bolotin (1994)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.3109/08982109909035551
Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its Encapsulation in Pegylated Liposomes
G. Colbern (1999)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
D. Drummond (1999)
Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
E. Forssen (1996)
10.1016/0005-2736(92)90084-Y
In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.
A. Horowitz (1992)
10.1016/0005-2736(95)00159-Z
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
D. Lasic (1995)
10.1056/NEJM198107163050305
The anthracycline antineoplastic drugs.
R. C. Young (1981)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1016/0005-2736(94)90004-3
Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles.
M. J. Parr (1994)
10.1016/s0021-9258(18)70226-3
Phosphorus assay in column chromatography.
G. R. Bartlett (1959)
10.1007/BF00874439
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
P. Guaglianone (2004)
10.3109/08982100009031097
Tumor Uptake and Therapeutic Effects of Drugs Encapsulated in Long-Circulating Pegylated Stealth® Liposomes
G. Colbern (2000)
Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.
S. S. Williams (1993)
10.1046/J.1365-2125.2003.01886.X
Population pharmacokinetics of liposomal daunorubicin in children.
G. Hempel (2003)
10.1007/s00280-003-0719-4
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
W. Zamboni (2003)
10.1016/S0005-2736(00)00359-X
Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance.
T. Peleg-Shulman (2001)
Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.
E. Forssen (1992)
10.1007/s002800050964
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin
M. Zucchetti (1999)
10.1097/00000421-199412000-00009
A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon
J. Eckardt (1994)
10.1016/0165-6147(94)90314-X
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
T. Allen (1994)
10.1097/00001813-200311000-00004
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion
J. Eucker (2003)
10.1046/j.1365-2141.2002.03292.x
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I–II study
A. Fassas (2002)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)



This paper is referenced by
10.2174/2211738504666160310002348
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin
T. Costich (2016)
10.1016/j.ejpb.2012.02.007
Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo.
S. Zalba (2012)
10.1016/J.IJPHARM.2007.02.011
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
T. Yang (2007)
Design and in-vitro/in-vivo evaluation in colon cancer cells of targeted oxaliplatin liposomes to epidermal growth factor receptor by conjugation of different ligands
S. Zalba (2015)
10.1517/17460441.1.6.549
Anthracyclines as effective anticancer drugs
Janos Nadas (2006)
10.1517/17425255.2011.614233
Functional characterization of drug uptake and metabolism in the heart
M. Weiss (2011)
10.2147/IJN.S97000
Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
D. R. Lee (2016)
10.1016/J.JDDST.2018.09.017
Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer
Upendra Bulbake (2018)
10.3797/SCIPHARM.0806-08
Preparation and In Vitro Evaluation of a Pegylated Nano-Liposomal Formulation Containing Docetaxel
A. Yousefi (2009)
10.1039/C3RA40883C
Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA
M. H. Oh (2013)
Development of Liposome Drug Delivery Systems for Anti-Glioma Therapy
M. Jain (2012)
10.1080/08982104.2016.1259628
Ethanol-based proliposome delivery systems of paclitaxel for in vitro application against brain cancer cells
M. Najlah (2018)
10.1371/journal.pone.0103736
Improved Efficacy and Reduced Toxicity of Doxorubicin Encapsulated in Sulfatide-Containing Nanoliposome in a Glioma Model
Jia Lin (2014)
10.1016/j.nano.2018.08.001
Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index.
Sebastian Kallus (2018)
The global technology revolution China, in-depth analyses : emerging technology opportunities for the Tianjin Binhai new area (TBNA) and the Tianjin economic-technological development area (TEDA)
R. Silberglitt (2009)
10.1016/j.nano.2017.12.003
PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Lingxuan Mo (2018)
10.1016/j.ijpharm.2009.03.018
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Jie Gao (2009)
A nanoliposome-based drug delivery system for cancer
J. Lin (2013)
In-vitro Characterization ofPEgyhtedLiposomes
eZ ImmunoGposomes (2015)
10.1021/jp309712b
Molecular dynamics simulations of DPPC bilayers using "LIME", a new coarse-grained model.
Emily M. Curtis (2013)
Investigations into Manufacturing Processes for a Liposomal Parenteral Nanoformulation to Solubilize Poorly Soluble Drug Substance
W. Omwoyo (2015)
10.3892/ol.2014.2494
Antitumor and antimetastasis effects of carboplatin liposomes with polyethylene glycol-2000 on SGC-7901 gastric cell-bearing nude mice
J. Zhang (2014)
10.2147/IJN.S8030
Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes
Preety Panwar (2010)
10.1080/10611860802201340
Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model
Yong-ming Zhang (2008)
10.1111/cns.12580
Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood–Brain Barrier in a Rat Model of Parkinson's Disease
Young-sook Kang (2016)
10.1097/CAD.0b013e328304d948
Reduced uptake of liposomal idarubicin in the perfused rat heart
P. Sermsappasuk (2008)
10.5772/22656
Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies
A. C. Pinto (2011)
10.1002/ANGE.200802585
Nanomedizin – Herausforderung und Perspektiven
K. Riehemann (2009)
10.1002/anie.200802585
Nanomedicine--challenge and perspectives.
K. Riehemann (2009)
Semantic Scholar Logo Some data provided by SemanticScholar